id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-300038-1fjb6b8e	Cantini, Fabrizio	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact	2020-04-23		.txt	text/plain	1261	81	48	According to a recent report 3 , COVID-19, the disease caused by SARS-CoV-2, is characterized by three clinical patterns: no symptoms, mild to moderate disease, severe pneumonia requiring admission to Intensive Care Unit (ICU) in up to 31% of the patients 3 . On this basis, we assessed the safety of baricitinib therapy combined with lopinavir-ritonavir in moderate COVID-19 pneumonia patients and we evaluated its clinical impact. All consecutive hospitalized patients (March 16 th -30 th ) with moderate COVID-19 pneumonia, older than 18 years, were treated for 2 weeks with baricitinib tablets 4 mg/day added to ritonavirlopinavir therapy. The last consecutive patients with moderate COVID-19 pneumonia receiving standard of care therapy (lopinavir/ritonavir tablets 250 mg/bid and hydroxychloroquine 400 mg/day/orally for 2 weeks) admitted before the date of the first baricitinib-treated patient served as controls. These preliminary results on 12 patients with moderate COVID-19 pneumonia confirmed the safety of baricitinib therapy in a clinical context different from RA 7 .	./cache/cord-300038-1fjb6b8e.txt	./txt/cord-300038-1fjb6b8e.txt